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INTRODUCTION
Gestational trophoblastic diseases are a heteroge-
nous group of conditions ranging from the benign
hydatidiform mole to the malignant choriocarci-
noma with complete hydatidiform mole occurring
in around 1 per 1,000 conceptions.1 Invasive mole
is a condition where a molar pregnancy, such as a
partial hydatidiform mole or complete hydatidi-
form mole, invades the wall of the uterus, poten-
tially spreading and metastasizing to other parts of
Abstract
Objective: Improving skill and knowledge to recognize and manage
a rare case of uterine perforation on invasive hydatidiform mole.
Method: Case report.
Result: A 42 years old Indonesian woman, Parity 2 Abortus 2 with
history of 2 c-sections and 2 curettage, came with chief complaint of
recurrent vaginal bleeding since 4 months before admission. Patient
had a history of previous curettage with indication of hydatidiform
mole and recurrent bleeding with no histopathology results. On ex-
amination we found a vesicular mass with infiltration, destroying
the right-front uterine corpus, size 8x6 cm with an internal echo
mass. Chest x-ray showed multiple nodules in the lung. The patient,
considered as low risk Gestational Trophoblastic Neoplasia patient
with FIGO Score of 6, underwent chemotherapy with 2 series of
methotrexate . Due to the non-declining level of  -hCG, the regimen
was added with EMACO. In the process of chemotherapy, the pa-tient’s
 -hCG declined but then she complained of major abdominal pain. Ex-
ploratory laparotomy was performed and we found a mass sized 5x5x5
cm on the right side of the uterus at the broad ligament with a rupture at
the posterior part of the mass sized 0.5x0.5 cm. Upon incision of the
uterus, we found a mass from the right side protruding to the isthmus of
the uterus. Histopathology showed necrosis, blood and chorionic villi in
myometrium corresponding to invasive mole. Patient was then given an-
other 5 series of EMACO and her condition was unremarkable during the
remaining course of treatment.
Conclusion: Invasive mole treatment is determined based on the
risk factors. Uterine perforation still occurred in this case regardless
of the decreasing hCG level during EMACO treatment. It emphasizes
the importance of clinical examination as chemotherapy respon-
siveness. Long-term treatment can have a good prognosis but good
collaboration between the gynecologist and the patient is essential.
[Indones J Obstet Gynecol 2014; 3: 162-165]
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Abstrak
Tujuan: Meningkatkan pengetahuan dan kemampuan untuk menge-
nali dan menangani kasus perforasi uterus pada mola hidatidosa in-
vasif.
Metode: Laporan kasus.
Hasil: Seorang perempuan Indonesia berusia 42 tahun, Paritas 2 Abor-
tus 2 dengan riwayat 2 seksio sesarea dan 2 kuretase, datang dengan
keluhan utama perdarahan pervaginam berulang sejak 4 bulan se-
belumnya. Pasien memiliki riwayat kuretase sebelumnya atas indikasi
mola hidatidosa dan perdarahan berulang tanpa disertai hasil histopa-
tologi. Pada pemeriksaan kami menemukan massa vesikular yang infil-
tratif dan menghancurkan korpus uterus kanan depan, berukuran 8x6
cm dengan struktur ekhointerna. Rontgen dada menunjukkan beberapa
nodul di paru-paru. Pasien didiagnosa sebagai pasien penyakit trofoblas
gestasional risiko rendah dengan Skor FIGO 6 dan diberi kemoterapi
dengan 2 seri methotrexat. Karena kadar  -hCG yang tidak menurun,
rejimen ditambahkan dengan EMACO. Dalam proses kemoterapi,
kadar  -hCG menurun tapi kemudian mengalami keluhan nyeri pe-
rut yang berat. Laparotomi eksplorasi dilakukan dan ditemukan
massa berukuran 5 x 5 x 5 cm di sisi rahim tepat pada ligamen latum
dengan bagian posterior massa telah pecah berukuran 0,5 x 0,5 cm.
Pada rahim didapatkan massa menonjol ke bagian isthmus. Hasil
histopatologi menunjukkan bagian nekrosis, darah dan villi korialis
dalam miometrium sesuai dengan mola invasif. Pasien kemudian
diberi terapi EMACO selama 5 siklus dengan kondisi baik selama
jangka waktu pengobatan.
Kesimpulan: Pengobatan mola invasif diklasifikasikan tergantung
faktor risiko untuk menentukan tatalaksana. Perforasi uterus masih
terjadi dalam kasus ini meskipun tingkat hCG terus menurun selama
pengobatan EMACO. Hal tesebut menekankan pentingnya pemerik-
saan klinis dalam menilai respons kemoterapi. Tata laksana bisa di-
lakukan jangka panjang dengan prognosis yang baik dengan kerja-
sama yang baik antara dokter dan pasien.
[Maj Obstet Ginekol Indones 2014; 3: 162-165]
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the body.2 It comprises only about 5-8% of all ges-
tational trophoblastic neoplasia (GTN).3 Here we
present a case of an Indonesian woman with ute-
rine perforation because of invasive mole in the
process of undergoing chemotherapy with metho-
trexate and even with EMACO.
CASE ILLUSTRATION
History, Examination and Management
We report a case of a 42-years old Indonesian
woman who came to our hospital with chief com-
plaint of recurrent vaginal bleeding since 4 months
prior to admission. Patient had a history of two
prior curettage in other hospital, 4 months and 2
months before, with indication of hydatidiform mo-
le and recurrent bleeding, respectively. Unfortuna-
tely no tissues were checked for pathology exami-
nation. Patient’s obstetric history included 2 cesa-
rean sections and 2 curettage on her previous
pregnancies.
On physical examination, we found the patient’s
condition to be unremarkable. On gynecological ex-
amination we found that the uterus was enlarged
with suspected adnexal mass on the right adnexa.
On ultrasonography we found a vesicular mass that
infiltrated and destroyed the right-front uterine
corpus, sized 8x6 cm with an internal echo mass,
blood like structure inside. Chest x-ray showed
multiple nodules in the lung.
The patient was then considered as low risk GTN
patient with FIGO Score of 6. She then underwent
chemotherapy with two series of methotrexate.
The baseline hCG level was 99,947 IU/ml. After the
first methothrexate, it decreased to 58,000 IU/ml
but then increased to 69,100 IU/ml after the se-
cond dose. Because of that, the regimen was added
with EMACO. After the 1st EMACO, the patient’s  -
hCG declined to 11,854 IU/ml but then she com-
plained of major abdominal pain. We then per-
formed an exploratory laparotomy and found a
mass sized 5x5x5 cm in the right side of the uterus
at the broad ligament with a rupture at the poste-
rior part of the mass sized 0.5x0.5 cm. Both of the
tubes and ovaries were within normal limits. Upon
incision of the uterus, we found a mass from the
right side protruding to the isthmus of the uterus.
Patient was then given another 5 series of
EMACO and  -hCG continued to decline to as low
as 1.45 IU/ml. The patient’s condition was unre-
markable during the remaining course of treat-
ment.
Figure 2. Intraoperative Finding Showing Mass with a Rupture at the Posterior Part.
Figure 1. Ultrasonography results: Malignant Trophoblastic that Invades the Right Uterine Corpus and Adnexa.
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DISCUSSION
Invasive mole is a condition where a molar preg-
nancy, such as a partial hydatidiform mole or com-
plete hydatidiform mole, invades the wall of the
uterus, potentially spreading and metastasizing to
other parts of the body (such as the vagina or
lungs).2,4,5 Its clinical characteristic are heteroge-
nous.4 Untreated invasive moles tend to invade the
uterine wall locally, which can result in uterine per-
foration and hemorrhage.6-8 It is characterized by
the persistence of edematous chorionic villi with
trophoblastic proliferation invading into the myo-
metrium.9 The presence of villi in the trophoblastic
tissue differentiates an invasive mole from chorio-
carcinoma.3,9,10
GTN is considered the most curable gynecologic
malignancy.11 The management of low-risk metas-
tatic GTN are similar to that of non-metastatic with
very good response of single agent chemotherapy
and those who fail can be treated with alternative
single agent or combination chemotherapy.5 Our
patient had a FIGO score of 6 and was considered
as low risk GTN. Data from a single center showed
that patients with a low-risk FIGO score but with
an hCG value exceeding 100,000 mIU/ml frequen-
tly require combination chemotherapy.12 The fai-
lure of treatment with methotrexate increased the
score to 8 in our patient and she was then con-
sidered as high risk. Chemoresistant case is when
the patient had a plateau (<50% fall in the  -hCG
levels) or an increased  -hCG level and/or deve-
lopment of new metastases for at least two con-
secutive cycles of combined chemotherapy.13
EMACO has the best effectiveness-to-toxicity ra-
tio, hence making it the first line regiment of com-
bination chemotherapy.14 Patients with disease re-
sistant to EMACO can be treated using EMAEP, a
regimen that substitutes cyclophosphamide and
vincristine on day 8 with cisplatin and etoposi-
de.14 Our patient had a lowered  -hCG level from
69,000 to 11,000 in the EMACO process, but clini-
cally the patient had abdominal pain that was later
shown as a uterine perforation. Serum hCG level is
the most relevant parameter in GTN detection as
well as in checking the efficacy of administered
therapy.15 In our case,  -hCG levels seem to res-
pond to the chemotherapy with the decreasing
level but uterine perforation still occurred, which
emphasized the importance of clinical examination
to assess chemotherapy responsiveness. Chemore-
sistance may not be the case for our patient. Other
regimens that were also effective in treating high-
risk refractory GTN includes BEP (bleomycin, eto-
poside, cisplatin), ICE (ifosfamide, carboplatin, eto-
poside), VIP (etoposide, ifosfamide, cisplatin) and
also FAEV (floxuridine, dactinomycin, etoposide,
and vincristine).14,16 Patients with chemoresistant
GTN have a bad prognosis and worse outcome
compared with patients with relapsed GTN.13
As far as we know, there have not been any case
reports on cesarean scar site of invasive mole.
There are no clear guidelines for the management
of cesarean scar site molar pregnancy. Current li-
terature reveals ultrasound-guided suction evacu-
ation to be the most widely used method and the
most successful.17 Moreover, some have adviced
use of oxytocyin during curettage.18
CONCLUSION
Invasive mole is a rare case with heterogenous
presentation. Its treatment are grouped between
the risk factor that should be counted beforehand
to determine its therapy. The uterine perforation
still occurred in this case despite the decreasing
hCG level during EMACO treatment. It emphasizes
the importance of clinical examination to assess
Figure 3. Histopathology Showed Necrosis, Blood and Villi Chorialis in Myometrium Corresponding to Invasive Mole.
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chemotherapy responsiveness. Long-term treat-
ment can yield good prognosis but good collabora-
tion between the gynecologist and the patient is
essential, as well as the need for support.
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